Strategic Vision: A Global Pharma Company
India Business Update
Q4FY22
35.0%
YOY
QoQ
% of Sales
5.0%
-8.3%
LUPIN
Q4 growth at 5% YoY; domestic formulations grew 13.3% YoY with contribution from key therapy areas
India Quarterly Sales (INR mn)
Lupin continues to outpace industry growth in Chronic
16,362
12,866
CAGR MAT Mar'18 - '22
15,435
Lupin Rank¹
14,733
13,511
Therapy
Market
Lupin
MAT
Mar'18
MAT
Mar'22
Acute
Chronic
11%
6%
12
15
12%
14%
4
4
Cardiac
12%
14%
3
3
Anti-diabetics
11%
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
16%
4
3
Respiratory
14%
15%
3
2
Strong Portfolio
BRANDS
RANK (MAT MAR'22)
·
GLUCONORM-G
44
3 in Top 100
HUMINSULIN
85
•
BUDAMATE
96
ONDERO
215
•
8 in Top 300
IVABRAD
229
GIBTULIO
231
TONACT
265
AJADUO
269
6th Rank in IPM; 65% Chronic contribution
For Lupin Respiratory & Gynae registered a double-digit growth in Q4
FY22
Two therapies- Cardiac & Anti Diabetics are above INR 1,000 Crore
sales
New divisions launched: Mind Next (CNS), Lupin Inspire (Diabetes)
Maxter Neo (Anti-infective)
8View entire presentation